Degenerative Disc Disease - Pipeline Review, H1 2018

  • ID: 4457562
  • Report
  • 63 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AnGes MG Inc
  • Biopharm GmbH
  • Bone Therapeutics SA
  • DiscGenics Inc
  • Osiris Therapeutics Inc
  • Samumed LLC
  • MORE
Degenerative Disc Disease - Pipeline Review, H1 2018

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Degenerative Disc Disease - Pipeline Review, H1 2018, provides an overview of the Degenerative Disc Disease (Musculoskeletal Disorders) pipeline landscape.

Degenerative disc disease is refers to degeneration of intervertebral discs of the spinal column. The main symptom of degenerative disc disease is pain, which often worsens during certain types of activity. Predisposing factors include aging and injury or trauma. Treatment includes non-steroidal anti-inflammatory drugs, muscle relaxants, pain relievers and antidepressants.

Report Highlights

The latest Pharmaceutical and Healthcare latest pipeline guide Degenerative Disc Disease - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Degenerative Disc Disease (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Degenerative Disc Disease (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Degenerative Disc Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 4, 1, 3 and 4 respectively.

Degenerative Disc Disease (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Degenerative Disc Disease (Musculoskeletal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Degenerative Disc Disease (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Degenerative Disc Disease (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Degenerative Disc Disease (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Degenerative Disc Disease (Musculoskeletal Disorders)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Degenerative Disc Disease (Musculoskeletal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Degenerative Disc Disease (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AnGes MG Inc
  • Biopharm GmbH
  • Bone Therapeutics SA
  • DiscGenics Inc
  • Osiris Therapeutics Inc
  • Samumed LLC
  • MORE
Introduction

Degenerative Disc Disease - Overview

Degenerative Disc Disease - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Degenerative Disc Disease - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Degenerative Disc Disease - Companies Involved in Therapeutics Development

AnGes MG Inc

Biopharm GmbH

BioRestorative Therapies Inc

Bone Therapeutics SA

DiscGenics Inc

Osiris Therapeutics Inc

Samumed LLC

TissueGene Inc

U.S. Stem Cell Inc

Yuhan Corp

Degenerative Disc Disease - Drug Profiles

AdipoCell - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ALLOB - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AMG-0101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AMG-0103 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BRTX-100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OTICR-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein for Bone Fracture, Degenerative Disc Disease, Erectile Dysfunction and Parkinson's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SM-04690 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Degenerative Disc Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Degenerative Disc Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TG-D - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

X-0002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

YH-14618 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Degenerative Disc Disease - Dormant Projects

Degenerative Disc Disease - Product Development Milestones

Featured News & Press Releases

Jan 15, 2018: USRM Reaches Key Sales Milestone of Proprietary Adipocell Product

Dec 18, 2017: Samumed Doses First Patient in Phase I Trial of SM04690 for Treatment of Degenerative Disc Disease

Nov 28, 2017: Degenerative Disc Patients Significantly Improve With USRM’s Adipocell

Oct 05, 2017: BioRestorative Therapies Announces Published Study of Licensed Technology to Treat Lumbar Degenerative Disc Disease

Oct 03, 2017: DiscGenics Receives FDA Allowance of IND to Commence Clinical Study of its Degenerative Disc Disease Therapy

Mar 09, 2017: Bone Therapeutics Completes Recruitment of 16 Patients in ALLOB PHASE I/IIA Delayed-Union Study

Feb 08, 2017: BioRestorative Therapies Receives FDA Clearance to Initiate Phase 2 Clinical Trial for the Treatment of Patients with Degenerative Disc Disease

Jan 09, 2017: BioRestorative Therapies Submits IND Application to FDA to Treat Patients with Degenerative Disc Disease

Nov 15, 2016: Samumed Presents Data for a Small Molecule Modulator of Wnt Pathway as a Potential Treatment for Degenerative Disc Disease

Nov 01, 2016: Samumed to present data on SM-04690 at American College of Rheumatology 2016 Annual Meeting

Oct 05, 2016: Bone Therapeutics reports positive efficacy data for the ALLOB Phase IIA spinal fusion trial

Sep 12, 2016: BioRestorative Therapies Announces Publication in Medical Journal of Positive Results of Long-Term Safety and Feasibility Study Using Cell Therapy to Treat Patients with Degenerative Disc Disease

May 03, 2016: Bone Therapeutics completes recruitment of its ALLOB Phase IIA spinal fusion study

Feb 24, 2016: Bone Therapeutics Presents ALLOB Pre-Clinical and Early Clinical Efficacy Data in Spinal Fusion at the ‘Clinical Applications of Stem Cells’ Conference

Feb 17, 2016: Bone Therapeutics treats 12 patients without safety concerns in ALLOB Phase IIA spinal fusion trial

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Degenerative Disc Disease, H1

Number of Products under Development by Companies, H1

Products under Development by Companies, H1

Number of Products by Stage and Target, H1

Number of Products by Stage and Mechanism of Action, H1

Number of Products by Stage and Route of Administration, H1

Number of Products by Stage and Molecule Type, H1

Degenerative Disc Disease - Pipeline by AnGes MG Inc, H1

Degenerative Disc Disease - Pipeline by Biopharm GmbH, H1

Degenerative Disc Disease - Pipeline by BioRestorative Therapies Inc, H1

Degenerative Disc Disease - Pipeline by Bone Therapeutics SA, H1

Degenerative Disc Disease - Pipeline by DiscGenics Inc, H1

Degenerative Disc Disease - Pipeline by Osiris Therapeutics Inc, H1

Degenerative Disc Disease - Pipeline by Samumed LLC, H1

Degenerative Disc Disease - Pipeline by TissueGene Inc, H1

Degenerative Disc Disease - Pipeline by U.S. Stem Cell Inc, H1

Degenerative Disc Disease - Pipeline by Yuhan Corp, H1

Degenerative Disc Disease - Dormant Projects, H1

List of Figures

Number of Products under Development for Degenerative Disc Disease, H1

Number of Products under Development by Companies, H1

Number of Products by Targets, H1

Number of Products by Stage and Targets, H1

Number of Products by Mechanism of Actions, H1

Number of Products by Stage and Mechanism of Actions, H1

Number of Products by Routes of Administration, H1

Number of Products by Stage and Routes of Administration, H1

Number of Products by Molecule Types, H1

Number of Products by Stage and Molecule Types, H
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AnGes MG Inc
  • Biopharm GmbH
  • BioRestorative Therapies Inc
  • Bone Therapeutics SA
  • DiscGenics Inc
  • Osiris Therapeutics Inc
  • Samumed LLC
  • TissueGene Inc
  • U.S. Stem Cell Inc
  • Yuhan Corp
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll